Tirbanibulin (Klisyri, Almirall) Improves AK Patient’s Satisfaction in Real-world Settings
Tirbanibulin (Klisyri, Almirall) performs as well in real-world practice as it does in clinical trials for actinic keratosis (AK), according to new analyses of Phase III, phase IV, and real-world studies presented at the 2025 American Academy of Dermatology’s annual meeting in Orlando, FL. Tirbanibulin is U.S. Food and Drug Administration-approved for the treatment of […]